Perfusion

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olivencia-Yurvati, A H
Right arrow Articles by Mallet, R T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olivencia-Yurvati, A H
Right arrow Articles by Mallet, R T
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Perfusion, Vol. 18, No. 1 suppl, 23-31 (2003)
DOI: 10.1191/0267659103pf625oa

Strategic leukocyte depletion reduces pulmonary microvascular pressure and improves pulmonary status post-cardiopulmonary bypass

A H Olivencia-Yurvati

Department of Surgery and the Cardiovascular Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA, ao-yurvati{at}unt.hsc.edu

C A Ferrara

Department of Surgery and the Cardiovascular Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA

N Tierney

Department of Surgery and the Cardiovascular Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA

N Wallace

Department of Surgery and the Cardiovascular Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA

R T Mallet

Department of Surgery and the Cardiovascular Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA

Cardiopulmonary bypass (CPB) precipitates inflammation that causes marked pulmonary dysfunction. Leukocyte filtration has been proposed to reduce these deleterious effects. Other studies show an improvement with aprotinin. We proposed that a combination of these two therapies would synergistically improve pulmonary outcomes. Two hundred and twenty-five patients participated in a randomized prospective study comparing pulmonary microvascular function and pulmonary shunt fraction postcoronary artery bypass grafting (CABG). The study group underwent leukocyte depletion with aprotinin during the procedure. Pulmonary microvascular function was assessed by pulmonary microvascular pressure (PMVP), a measure of pulmonary capillary edema, and pulmonary function was evaluated by comparing pulmonary shunt fractions. Elevated PMVP and increased pulmonary shunting compromise pulmonary performance. The leukocyte-depleted group had significantly reduced PMVP and pulmonary shunt fraction for at least the first 24 hours postbypass. The combination of strategic leukocyte filtration and aprotinin therapy can effectively reduce postoperative decline in pulmonary function.

Cardiopulmonary bypass precipitates a variety of inflammatory effects that can cause marked pulmonary dysfunction to the point of respiratory failure, necessitating prolonged mechanical ventilation. Leukocyte filtration has been investigated previously and appears to be beneficial in improving pulmonary outcome by preventing direct neutrophil-induced inflammatory injury. Recent studies of leukocyte reduction profiles suggest that leukoreduction via leukofiltration is short lived with filter saturation occurring 30 - 45 minutes after onset of filtration. This phenomenon may explain the limited utility observed with higher risk patients. These patients typically require longer pump runs, so leukocyte reduction capability is suboptimal at the time of pulmonary vascular reperfusion. To more effectively protect the lung from reperfusion injury, leukocyte filtration can be delayed so that reduction of activated neutrophils is maximal at the time of pulmonary vascular reperfusion. It is, thus, conceivable that a timely use of arterial line leukoreducing filters may improve, more substantially, pulmonary function postbypass.

Two hundred and twenty-five isolated coronary revascularization patients participated in this prospective, randomized trial. The patients received moderately hypothermic CBP alone (control group: n = 110) or combined with leukocyte depletion, initiated 30 minutes before crossclamp release, with filters placed in the bypass circuit (study group: n = 115). All patients also received full Hammersmith aprotinin dosing during the operation.

Pulmonary microvascular pressures were lower in the study group at three hours postbypass, and continued to fall until 24 hours postbypass. In contrast, the control group measured a rise in PMVP and a continued plateau throughout 24 hours postbypass (p B /0.028). The calculated pulmonary shunt fraction also was reduced significantly throughout the study interval, with the greatest reduction occurring approximately three to six hours post-CPB (p B /0.002). Shunt fractions eventually converged at 24 hours postbypass. Outcome measures included hospital charges and length of stay, which were also markedly reduced in the treatment group.

Increasing PMVPs are a direct reflection of pulmonary capillary edema, which, in conjunction with increased pulmonary shunt ratio, lead to an overall worsening of pulmonary function. Intraoperative strategic leukocyte filtration combined with aprotinin treatment improves post-CPB lung performance by reducing significantly the reperfusion inflammatory response and its sequelae. These benefits are manifested by reductions in ventilator times, hospital stay and patient morbidity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
T. Gourlay, A. H. Olivencia-Yurvati, and S. Gunaydin
STS Blood Conservation Guidelines: The Role of Leukocyte Filtration
Ann. Thorac. Surg., March 1, 2008; 85(3): 1138 - 1139.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
O. Warren, C. Alexiou, R. Massey, D. Leff, S. Purkayastha, J. Kinross, A. Darzi, and T. Athanasiou
The effects of various leukocyte filtration strategies in cardiac surgery
Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 665 - 676.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
E. Hickey, T. Karamlou, J. You, and R. M. Ungerleider
Effects of Circuit Miniaturization in Reducing Inflammatory Response to Infant Cardiopulmonary Bypass by Elimination of Allogeneic Blood Products
Ann. Thorac. Surg., June 1, 2006; 81(6): S2367 - S2372.
[Abstract] [Full Text] [PDF]


Home page
JAOA: Journal of the American Osteopathic AssociationHome page
A. H. O-Yurvati, M. S. Carnes, M. B. Clearfield, S. T. Stoll, and W. J. McConathy
Hemodynamic Effects of Osteopathic Manipulative Treatment Immediately After Coronary Artery Bypass Graft Surgery
J Am Osteopath Assoc, October 1, 2005; 105(10): 475 - 481.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. F. Salamonsen, J. Anderson, M. Anderson, M. Bailey, G. Magrin, and F. Rosenfeldt
Total Leukocyte Control for Elective Coronary Bypass Surgery Does Not Improve Short-Term Outcome
Ann. Thorac. Surg., June 1, 2005; 79(6): 2032 - 2038.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. Gourlay
Invited commentary
Ann. Thorac. Surg., August 1, 2004; 78(2): 642 - 643.
[Full Text] [PDF]


Home page
PerfusionHome page
A. H Olivencia-Yurvati, N. Wallace, S. Ford, and R. T Mallet
Leukocyte filtration and aprotinin: synergistic anti-inflammatory protection
Perfusion, January 1, 2004; 19(1_suppl): S13 - S19.
[Abstract] [PDF]